Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen

Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages also recently issued reports on SNDX. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $56.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. Barclays upped their price target on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. UBS Group increased their price target on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. dropped their price objective on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.30.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $21.71 on Friday. The business has a 50-day simple moving average of $20.86 and a two-hundred day simple moving average of $17.99. The stock has a market cap of $1.89 billion, a PE ratio of -6.60 and a beta of 0.46. Syndax Pharmaceuticals has a 12-month low of $8.58 and a 12-month high of $22.73. The company has a quick ratio of 4.42, a current ratio of 4.64 and a debt-to-equity ratio of 2.78.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, March 2nd. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.12). The business had revenue of $68.73 million for the quarter. Syndax Pharmaceuticals had a negative return on equity of 175.50% and a negative net margin of 165.37%.Syndax Pharmaceuticals’s revenue was up 792.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.10) earnings per share. Analysts anticipate that Syndax Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Keith A. Goldan sold 3,410 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the completion of the sale, the chief financial officer directly owned 140,429 shares of the company’s stock, valued at $2,953,221.87. The trade was a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael A. Metzger sold 17,159 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the completion of the transaction, the chief executive officer owned 491,690 shares in the company, valued at approximately $10,340,240.70. The trade was a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,063 shares of company stock worth $628,332 in the last quarter. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds have recently bought and sold shares of SNDX. Sector Gamma AS purchased a new position in Syndax Pharmaceuticals in the third quarter worth $3,243,000. Franklin Resources Inc. increased its position in shares of Syndax Pharmaceuticals by 14.5% during the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company’s stock valued at $22,098,000 after purchasing an additional 298,272 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Syndax Pharmaceuticals by 112.2% during the 2nd quarter. Schroder Investment Management Group now owns 122,163 shares of the company’s stock worth $1,144,000 after purchasing an additional 64,598 shares during the period. Keybank National Association OH purchased a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth about $2,305,000. Finally, Aisling Capital Management LP boosted its holdings in shares of Syndax Pharmaceuticals by 28.5% in the 2nd quarter. Aisling Capital Management LP now owns 1,316,806 shares of the company’s stock worth $12,325,000 after buying an additional 291,806 shares during the last quarter.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Robust commercial revenue — Syndax reported $68.7M in Q425 and $172.4M for FY2025, driven by product sales; Revuforj (revumenib) net revenue was $44.2M in Q4 (up 38% vs Q3) and Niktimvo (axatilimab‑csfr) net revenue was $56.0M in Q4 (up 22% vs Q3). Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue topped expectations and showed large year‑over‑year growth (Q4 revenue up ~792% YoY), which investors may view as validation of the commercialization ramp. Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress: enrollment completed in the Phase 2 IPF trial of axatilimab with topline data expected in 4Q26 — a clear near‑to‑mid‑term catalyst to monitor. Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst consensus remains constructive — the stock carries an average rating of “Moderate Buy,” which may support sentiment but is not a new catalyst by itself. Syndax Pharmaceuticals, Inc. Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Company hosted an earnings conference call and published slides; these materials provide additional detail on commercialization cadence and guidance drivers. View Press Release / Slide Deck
• Negative Sentiment: EPS missed estimates — Syndax reported a Q4 loss of $0.78 per share versus consensus around ($0.64)–($0.66), signaling continued losses and pressure on near‑term profitability. Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Profitability metrics remain weak — the company reported a negative net margin and negative return on equity, underscoring that top‑line growth has yet to translate into earnings. Syndax Q4 Earnings Snapshot / Conference Call

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.